Frontier Medicines

Frontier Medicines is a precision medicine company that builds a discovery and development platform aimed at disease-causing proteins long considered undruggable. Its technical work spans chemoproteomics, proteomics, covalent drug discovery, small-molecule therapeutics and machine learning, applied to the identification of novel covalent binding sites across the proteome.

Two capabilities anchor the effort. The Druggability Atlas is a proprietary mapping resource that surfaces novel covalent binding sites and actionable leads, with thousands of opportunities identified across the proteome. The company's lead program targets KRAS G12C, designed to inhibit both the activated and inactive forms of the protein in genetically-defined patient populations, with relevance to non-small cell lung, colorectal and pancreatic cancers.

Frontier Medicines operates from South San Francisco and Boston, and has entered a global strategic collaboration with AbbVie. The company describes its orientation as patient-focused and mission-driven, pursuing what it characterises as potentially groundbreaking medicines.